These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36692920)

  • 1. Expensive Drugs for Rare Diseases in Canada: Time for Action Everywhere and by Everyone.
    Sirrs S; Anderson H; Jiwani B; Lun E; Nakagawa B; Regier D; Rizzardo S; McFarlane A
    Healthc Pap; 2023 Jan; 21(1):74-80. PubMed ID: 36692920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can Managed Access Agreements Mitigate Evidentiary, Economic and Ethical Issues with Access to Expensive Drugs for Rare Diseases in the Canadian Context?
    McPhail M; Bubela T
    Healthc Pap; 2023 Jan; 21(1):59-65. PubMed ID: 36692918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expensive Drugs for Rare Diseases in Canada: What Value and at What Cost?
    Sirrs S; Anderson H; Jiwani B; Lynd LD; Lun E; Nakagawa B; Regier D; Rizzardo S; McFarlane A
    Healthc Pap; 2023 Jan; 21(1):10-26. PubMed ID: 36692912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?
    Menon D; Clark D; Stafinski T
    Healthc Policy; 2015 Aug; 11(1):15-32. PubMed ID: 26571466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits?
    Rawson NSB
    Orphanet J Rare Dis; 2022 Jun; 17(1):218. PubMed ID: 35698235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
    Hughes-Wilson W; Palma A; Schuurman A; Simoens S
    Orphanet J Rare Dis; 2012 Sep; 7():74. PubMed ID: 23013790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Federal Funding for Expensive Drugs for Rare Diseases: How Do We Pick and Choose?
    Lexchin J; Sirrs S
    Healthc Policy; 2024 Aug; 19(4):19-26. PubMed ID: 39229659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expensive Drugs for Rare Diseases: "Canada, We Have a Problem Here".
    Lexchin J
    Healthc Pap; 2023 Jan; 21(1):4-8. PubMed ID: 36692911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory approval and public drug plan listing of new drugs for rare disorders in Canada and New Zealand.
    Rawson NSB
    J Popul Ther Clin Pharmacol; 2020 Jun; 27(2):e58-e67. PubMed ID: 32543163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
    Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alignment of health technology assessments and price negotiations for new drugs for rare disorders in Canada: Does it lead to improved patient access?
    Rawson NSB
    J Popul Ther Clin Pharmacol; 2020 Feb; 27(1):e48-e64. PubMed ID: 32124580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada.
    Morgan SG; Gagnon MA; Mintzes B; Lexchin J
    Healthc Policy; 2016 Aug; 12(1):18-36. PubMed ID: 27585023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific, Fair and Transparent: A Canadian Process for Funding Drugs for Rare Diseases.
    Stevenson H
    Healthc Pap; 2023 Jan; 21(1):28-33. PubMed ID: 36692913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When everyone is an orphan: against adopting a U.S.-styled orphan drug policy in Canada.
    Herder M
    Account Res; 2013; 20(4):227-69. PubMed ID: 23805831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries.
    Ward LM; Chambers A; Mechichi E; Wong-Rieger D; Campbell C
    Orphanet J Rare Dis; 2022 Mar; 17(1):113. PubMed ID: 35246200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expensive Drug Prices for Rare Cancers: Are Patients Truly Benefitting?
    Jenei K; Gyawali B
    Healthc Pap; 2023 Jan; 21(1):44-51. PubMed ID: 36692916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceutical policies in Canada: another example of federal-provincial discord.
    Anis AH
    CMAJ; 2000 Feb; 162(4):523-6. PubMed ID: 10701389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
    Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare sustainability and the challenges of innovation to biopharmaceuticals in Canada.
    Rosenberg-Yunger ZR; Daar AS; Singer PA; Martin DK
    Health Policy; 2008 Sep; 87(3):359-68. PubMed ID: 18358556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.